Against most test strains of Gram-negative bacilli, the in vitro effect of FR-31564 together with 9-lactam antibiotics or trimethoprim was strongly synergistic; with tetracycline and nalidixic acid the effect was additive; and with gentamicin and sulfamethoxazole the effect was additive or antagonistic.
FR-31564 was markedly synergistic with ;3-lactam antibiotics against i3-lactam antibioticresistant Gram-negative bacilli such as Klebsiella pnemnoniae, Enterobacter aerogenes, E. cloacae, Citrobacter freundii and Serratia uarcescens.
The combination of FR-31564 with ;3-lactam antibiotics effected a reduction of MICs against most of the test strains to clinically achievable concentrations in human serum. Bactericidal Effect Nutrient broths containing concentrations of 40 jig/ml (1/5 the MIC) of FR-31564 alone and in combination with 1, 5, 25 and 125 tcg/ml of 13-lactam antibiotics were inoculated with 0.5 % of an overnight culture of E. aerogenes No. 7 to obtain about 108 colony forming units (c.f.u.)/ml, and incubated at 37°C for 3 hours. Viable cell counts in the culture fluids were determined by conventional plating techniques.
Results

FIC Index
The MICs of FR-31564 alone and in combination with the other test antibiotics were determined against test organisms resistant to FR-31564. The synergistic effect between FR-31564 and the other antibiotics was evaluated by FIC index. Table I shows that FR-31564 was synergistic with cefazolin against all strains of E. aerogenes, E. cloacae, C. freundii and S. aureus, and against 80, 60, and 40% of the test strains of S. marcescens, P. vulgaris and K. pneumoniae respectively. However, FR-31564 was additive with cefazolin against 83 % of E. coli strains. The combination of FR-31564 with cephalexin showed synergism against all strains of S. marcescens and C. freundii, and against 80 % of each of the strains of K. pneumoniae, E.
aerogenes and P. vulgaris tested. On the other hand, the frequency of synergism between FR-31564 and cephalexin was low against P. aeruginosa (50%), E. cloacae (20%) and E. coli (17%). The combination of FR-31564 with cephalexin exerted scarcely any synergistic effect against strains of S. aureus.
FR-31564 was synergistic with ampicillin and carbenicillin against many of the test organisms but was not synergistic with carbenicillin against S. aureus. Synergism was seen less frequently when FR-31564 was combined with nalidixic acid and tetracycline than when combined with the above 3-lactam antibiotics. FR-31564 was significantly synergistic with trimethoprim against all organisms except P. vulgaris and P. aeruginosa. FR-31564 was slightly synergistic with sulfamethoxazole and gentamicin against the organisms tested.
These results indicate that the lactam antibiotics and trimethoprim were suitable partners for synergistic combinations with FR-31564 and gave synergistically effective combinations against K.
pneumoniae, E. aerogenes, E. cloacae, S. marcescens and C. freundii. 1 : 4) were compared to evaluate the antibacterial efficacy of these combination's. Table 2 shows the mean MICs of FR-31564 alone and in combination with cefazolin, cephalexin, ampicillin or carbenicillin against 5 or 6 strains of each of the test organisms. MICs against S. aureus, which is highly susceptible to /3-lactam antibiotics but not to FR-31564, were either slightly reduced or unaffected by the combination of two drugs. 
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The reduction of MIC values against organisms highly resistant to the antibiotics tested was generally significant: the degree of synergism was high against E. cloacae, E. aerogenes, S. marcescens, C. freundii and P. vulgaris.
The synergism of FR-31564 with 4 kinds of 11-lactam antibiotics was compared with that of fosfomycin against strains of E. coli, E. cloacae, E. aerogenes and C. freundii (Table 3) . Mean MICs of FR-31564 -;~-lactam antibiotic combinations for 21 strains of E. cloacae were markedly lower than those 
Discussion
Despite the advent of many new antimicrobial agents, serious infections due to Gram-negative bacilli including opportunistic pathogens remain on the increase in compromised hosts" 12) Many of the pathogens causing such infections are resistant to antibiotics in common use. We, therefore extensively investigated synergism between antibiotics in order to enhance their therapeutic effect. Synergism increases antibacterial activity; it may expand the antibacterial spectrum and may decrease development of resistant cells. Various antibiotic combinations are widely used in clinical treatment and provide the following mechanisms of synergism: 1) inhibition at two sites of a biochemical pathway (trimethoprim -sulfamethoxazole)13', 2) prevention of enzymatic hydrolysis by 3-lactamase (ampicillin -cloxacillin, 3-lactam antibiotics and clavulanic acids or CP45899)11-'1', 3) enhancement of penetration by aminoglycosides to the active site (j3-lactam antibiotics and aminoglycosides)1", and 4) difference of affinity for penicillin binding proteins","'.
In addition to the above combinations, phosphonic acid antibiotics such as fosfomycin and alafosfalin have recently been reported to act synergistically with various kinds of antibiotics, especially with 3-lactam antibiotics. FR-31564 also was markedly synergistic with 3-lactam antibiotics and trimethoprim. The extent of in vitro synergism is generally estimated on the basis of the FIC-index. The MICs against most of the test strains of various organisms can be reduced to concentrations achievable in human serum by synergistic combinations. Although most of the strains were highly resistant to individual antibiotics, the combination of FR-31564 with (3-lactam antibiotics gave often a high efficiency. The combinations of FR-31564 and /3-lactam antibiotics were generally more active in vitro than those of fosfomycin with 3-lactam antibiotics. The high ability of FR-31564 to penetrate the bacterial membrane'' may contribute to its synergistic effect when used with (3-lactam antibiotics, although the mechanism of synergism between phosphonic acid antibiotics and ;3-lactam antibiotics has not been clarified. Recent reports have shown that resistant mutants appear at high frequency in the presence of fosfomycin and the same phenomenon has also been observed for FR-31564.
Since there is a possibility that resistant mutants may arise by the clinical use of FR-31564 alone, the combination of FR-31564 and j3-lactam antibiotics should be considered in order to avoid this potential clinical problem.
